Data from EMA (European Medicines Agency) - Curated by Marshall Pearce - Last updated 10 November 2017
- in adults and children aged 1 to 18 years on haemodialysis and adult patients on peritoneal dialysis.
- in adults with renal insufficiency not yet undergoing dialysis for the treatment of severe anaemia of renal origin accompanied by clinical symptoms in patients.
Binocrit is indicated in adults receiving chemotherapy for solid tumours, malignant lymphoma or multiple myeloma, and at risk of transfusion as assessed by the patient’s general status (e.g. cardiovascular status, pre-existing anaemia at the start of chemotherapy) for the treatment of anaemia and reduction of transfusion requirements.
Binocrit is indicated in adults in a predonation programme to increase the yield of autologous blood.
Treatment should only be given to patients with moderate anaemia (haemoglobin [Hb] concentration range between 10 to 13 g/dl [6.2 to 8.1 mmol/l], no iron deficiency), if blood saving procedures are not available or insufficient when the scheduled major elective surgery requires a large volume of blood (4 or more units of blood for females or 5 or more units for males).
Binocrit is indicated for non-iron deficient adults prior to major elective orthopaedic surgery, having a high perceived risk for transfusion complications to reduce exposure to allogeneic blood transfusions. Use should be restricted to patients with moderate anaemia (e.g. haemoglobin concentration range between 10 to 13 g/dl or 6.2 to 8.1 mmol/l) who do not have an autologous predonation programme available and with expected moderate blood loss (900 to 1,800 ml).
An epgonline.org Learning Zone (LZ) is an area of the site dedicated to providing detailed self-directed medical education about a disease, condition or procedure.
Experts discuss the use of non-vitamin K oral anticoagulants in the treatment and prevention of stroke, deep vein thrombosis and pulmonary embolism in atrial fibrillation patients.
See information on best practice in solid organ transplantation, and expert discussions on related hot topics.
Allogeneic Stem Cell Transplantation for Children and Adolescents With Acute Lymphoblastic Leukaemia
The ALL SCTped 2012 FORUM is a multinational, multi-centre, randomized, controlled, prospective seamless phase II/III study for the therapy and...
Added 5 years ago
Pharmacokinetics of anidulafungin (Ecalta ®) given intravenously as antifungal prophylaxis to recipients of an allogeneic haematopoietic stem cell transplant following myeloablative chemotherapy or patients receiving intensive chemotherapy for AML-MDS who are at high risk for developing invasive fungal disease
To determine the pharmacokinetics of anidulafungin given once in every 2 days (q48h) or once in every 3 days (q72h)...
Added 8 years ago
CML-SCT -IBFM Study Allogeneic stem cell transplantation for children and Adolescents with CML: Conditioning regimen, donor selection, supportive care and diagnostic procedures.
To evaluate whether transplant related mortality following allogeneic stem cell transplantation from unrelated donors for CML can be reduced by...
Added 9 years ago
To evaluate whether HSCT from matched family or unrelated donors (MD) is equivalent to the HSCT from matched sibling donors...
Added 11 years ago
A Study to Investigate Different Doses of BAY1213790 to Prevent Blood Clots in Patients Undergoing Elective Total Knee Replacement Surgery (FOXTROT)
This study is to compare the study drug BAY1213790 to existing therapies, ie Enoxaparin or Apixaban for the prevention of blood clotting and safety in patients undergoing total knee arthroplasty (TKA).
Added 11 days ago
Hemolytic-uremic syndrome (HUS) is the triad of microangiopathic hemolytic anemia (MAHA), thrombocytopenia, and acute kidney injury (AKI); the main cause of multi-organ failure is related to thrombotic microangiopathy (TMA).
Added 6 months ago
Eculizumab is a safe and effective treatment in pediatric patients with atypical hemolytic uremic syndrome.
Atypical hemolytic uremic syndrome (aHUS) is caused by alternative complement pathway dysregulation, leading to systemic thrombotic microangiopathy (TMA) and severe...
Added 1 year ago
Improved renal recovery in patients with atypical hemolytic uremic syndrome following rapid initiation of eculizumab treatment.
Background: Eculizumab is approved for atypical hemolytic uremic syndrome (aHUS). Guidelines discuss the importance of prompt treatment. We report a...
Added 1 year ago
British Committee for Standards in Haematology Guidelines on the Identification and Management of Pre-Operative Anaemia
A Guideline Development Group (GDG) was commissioned by the British Committee for Standards in Haematology (BCSH), with members variously having...
Added 2 years ago
This guideline covers the management of anaemia in adults, children and young people with a clinical diagnosis of anaemia associated...
Added 2 years ago
The guideline group was selected to be representative of UK-based experts in the clinical and laboratory fields of iron metabolism,...
Added 4 years ago
|Agency product number||EMEA/H/C/000725|
|Date First Approved||28-08-2007|
|Type||Medicinal product subject to restricted medical prescription|
|Marketing authorisation holder||Sandoz GmbH|